---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-25-000082"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:18:35.210522+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Neurogene reports Q2 net loss $22M; cash $274.5M, FDA agrees on registrational trial design for Rett gene therapy

## Summary
- Net loss of $22.0M for Q2 2025 vs $18.5M in Q2 2024; R&D expenses $19.4M vs $15.7M.
- Cash, cash equivalents and short-term investments $274.5M as of June 30, 2025; runway into early 2028.
- FDA provided written agreement on key elements of Embolden registrational trial for NGN-401; sample size refined to propose 20 participants.
- Completed dosing in Phase 1/2 NGN-401 trial; last 5 participants dosed in H1 2025; updated clinical data expected H2 2025.
- No evidence of HLH/hyperinflammatory syndrome in any NGN-401 participant at 1E15 vg dose level as of press date.

## SEC filing metadata
- accession: 0001404644-25-000082
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000082/0001404644-25-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000082/ngne-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-25-000082
- JSON: https://secwatch.observer/filing/0001404644-25-000082.json
- Plain text: https://secwatch.observer/filing/0001404644-25-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.